Verona Pharma plc (VRNA)

15,59 -0,13 (-0,83%) Börsenschluss: 04:00PM EDT

Verona Pharma plc

3 More London Riverside
London SE1 2RE
United Kingdom
44 20 3283 4200
https://www.veronapharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 79

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. David S. Zaccardelli Pharm.D.	President, CEO & Executive Director	1,27M	N/A	1964
Mr. Mark W. Hahn	Chief Financial Officer	858,29k	N/A	1963
Dr. Kathleen A. Rickard M.D.	Chief Medical Officer	650,83k	N/A	1958
Mr. Andrew Fisher	General Counsel	N/A	N/A	1970
Ms. Victoria Stewart	Director of Communications	N/A	N/A	N/A
Mr. Matthew Casbon	VP of Sales, Marketing & Training	N/A	N/A	N/A
Ms. Ostra Jewell	Senior Vice President of Human Resources	N/A	N/A	N/A
Dr. Tara Rheault M.P.H., Ph.D.	Chief Development Officer	N/A	N/A	1977
Mr. Christopher Martin	Chief Commercial Officer	N/A	N/A	N/A
Ms. Caroline Diaz	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.

Corporate Governance

Verona Pharma plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.